These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38821604)

  • 1. A Potential Combination of Targeting HSP90 and mTOR in Breast Cancer Cell Growth, Migration, and Invasion Through Inhibiting AKT Phosphorylation and F-actin Organization.
    Suwannalert P; Panpinyaporn P; Wantanachaisaeng P; Teeppaibul T; Khumsri W; Koomsang T; Payuhakrit W; Naktubtim C
    Anticancer Res; 2024 Jun; 44(6):2555-2565. PubMed ID: 38821604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heat shock protein 90 is a promising target for effective growth inhibition of gastrointestinal neuroendocrine tumors.
    Gloesenkamp C; Nitzsche B; Lim AR; Normant E; Vosburgh E; Schrader M; Ocker M; Scherübl H; Höpfner M
    Int J Oncol; 2012 May; 40(5):1659-67. PubMed ID: 22246317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synuclein γ protects Akt and mTOR and renders tumor resistance to Hsp90 disruption.
    Liang W; Miao S; Zhang B; He S; Shou C; Manivel P; Krishna R; Chen Y; Shi YE
    Oncogene; 2015 Apr; 34(18):2398-405. PubMed ID: 24954510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ascofuranone suppresses invasion and F-actin cytoskeleton organization in cancer cells by inhibiting the mTOR complex 1 signaling pathway.
    Jeong YJ; Hwang SK; Magae J; Chang YC
    Cell Oncol (Dordr); 2020 Oct; 43(5):793-805. PubMed ID: 32488849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HSP90 modulates actin dynamics: inhibition of HSP90 leads to decreased cell motility and impairs invasion.
    Taiyab A; Rao ChM
    Biochim Biophys Acta; 2011 Jan; 1813(1):213-21. PubMed ID: 20883729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated expression of HSP90 and the antitumor effect of an HSP90 inhibitor via inactivation of the Akt/mTOR pathway in undifferentiated pleomorphic sarcoma.
    Bekki H; Kohashi K; Maekawa A; Yamada Y; Yamamoto H; Harimaya K; Hakozaki M; Nabeshima K; Iwamoto Y; Oda Y
    BMC Cancer; 2015 Oct; 15():804. PubMed ID: 26502919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thymoquinone affects hypoxia-inducible factor-1α expression in pancreatic cancer cells via HSP90 and PI3K/AKT/mTOR pathways.
    Zhao ZX; Li S; Liu LX
    World J Gastroenterol; 2024 Jun; 30(21):2793-2816. PubMed ID: 38899332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Curbing Breast Cancer by Altering V-ATPase Action on F-Actin, Heterochromatin, ETV7 and mTORC2 Signaling.
    Khan ZS; Hussain F
    Cell Physiol Biochem; 2024 Jun; 58(3):250-272. PubMed ID: 38865588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic anti-tumor effect of 17AAG with the PI3K/mTOR inhibitor NVP-BEZ235 on human melanoma.
    Calero R; Morchon E; Martinez-Argudo I; Serrano R
    Cancer Lett; 2017 Oct; 406():1-11. PubMed ID: 28774796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MPPa-PDT suppresses breast tumor migration/invasion by inhibiting Akt-NF-κB-dependent MMP-9 expression via ROS.
    Huang L; Lin H; Chen Q; Yu L; Bai D
    BMC Cancer; 2019 Nov; 19(1):1159. PubMed ID: 31783821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quercetin suppresses the mobility of breast cancer by suppressing glycolysis through Akt-mTOR pathway mediated autophagy induction.
    Jia L; Huang S; Yin X; Zan Y; Guo Y; Han L
    Life Sci; 2018 Sep; 208():123-130. PubMed ID: 30025823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of rapamycin and 17-allylamino-17-demethoxygeldanamycin abrogates Akt activation and potentiates mTOR blockade in breast cancer cells.
    Roforth MM; Tan C
    Anticancer Drugs; 2008 Aug; 19(7):681-8. PubMed ID: 18594209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiproliferative Activity of Carnosic Acid is Mediated via Inhibition of Cell Migration and Invasion, and Suppression of Phosphatidylinositol 3-Kinases (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Signaling Pathway.
    Zhao L; Zhang J; Fan Y; Li Y
    Med Sci Monit; 2019 Oct; 25():7864-7871. PubMed ID: 31631173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Asperolide A prevents bone metastatic breast cancer via the PI3K/AKT/mTOR/c-Fos/NFATc1 signaling pathway.
    Jiang W; Rixiati Y; Huang H; Shi Y; Huang C; Jiao B
    Cancer Med; 2020 Nov; 9(21):8173-8185. PubMed ID: 32976685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SNX-2112, a novel Hsp90 inhibitor, induces G2/M cell cycle arrest and apoptosis in MCF-7 cells.
    Wang SX; Ju HQ; Liu KS; Zhang JX; Wang X; Xiang YF; Wang R; Liu JY; Liu QY; Xia M; Xing GW; Liu Z; Wang YF
    Biosci Biotechnol Biochem; 2011; 75(8):1540-5. PubMed ID: 21821931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 17AEP-GA, an HSP90 antagonist, is a potent inhibitor of glioblastoma cell proliferation, survival, migration and invasion.
    Miekus K; Kijowski J; Sekuła M; Majka M
    Oncol Rep; 2012 Nov; 28(5):1903-9. PubMed ID: 22941268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HSP90 inhibitor AUY922 abrogates up-regulation of RTKs by mTOR inhibitor AZD8055 and potentiates its antiproliferative activity in human breast cancer.
    Chen SM; Guo CL; Shi JJ; Xu YC; Chen Y; Shen YY; Su Y; Ding J; Meng LH
    Int J Cancer; 2014 Nov; 135(10):2462-74. PubMed ID: 24706460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
    Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
    Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2348-56. PubMed ID: 18281615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel 4-aminoquinazoline derivative, DHW-208, suppresses the growth of human breast cancer cells by targeting the PI3K/AKT/mTOR pathway.
    Wang S; Zhang Y; Ren T; Wu Q; Lu H; Qin X; Liu Y; Ding H; Zhao Q
    Cell Death Dis; 2020 Jun; 11(6):491. PubMed ID: 32606352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multi-drug loaded micelles delivering chemotherapy and targeted therapies directed against HSP90 and the PI3K/AKT/mTOR pathway in prostate cancer.
    Le B; Powers GL; Tam YT; Schumacher N; Malinowski RL; Steinke L; Kwon G; Marker PC
    PLoS One; 2017; 12(3):e0174658. PubMed ID: 28350865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.